Cristina Larkin - Chief Operating Officer at Spero Therapeutics, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Stock	63.6K	$80.7K	$1.27	Feb 1, 2022	Direct
Stock Option (Right to Buy)	53.2K	$59.6K	$1.12	Feb 1, 2022	Direct	Common Stock

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.